Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.
|Numero di pagine
|Journal of the European Academy of Dermatology and Venereology
|Stato di pubblicazione
|Pubblicato - 2012